Evidence map›Paper›PMID 35681590›Full record

ReviewCancers2022

Implementation of HPV Tests in Latin America: What We Learned; What Should We Have Learned, and What Can We Do Better?

Luani Rezende Godoy, Júlio César Possati-Resende, Yasmin Medeiros Guimarães, Priscila Grecca Pedrão, Ricardo Dos Reis, Adhemar Longatto-Filho

Abstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Risk Profile of High-grade Cervical Lesions and Cervical Cancer Considering the Combination of Cytology, HPV Genotype, and Age among Women Undergoing Colposcopy.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2023
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Luani Rezende GodoyMolecular Oncology Research Center, Barretos Cancer Hospital, São Paulo 14784-400, Brazil.ORCID 0000-0002-1559-293X
Júlio César Possati-ResendeDepartment of Prevention Oncology, Barretos Cancer Hospital, São Paulo 14784-400, Brazil.ORCID 0000-0002-7869-3885
Yasmin Medeiros GuimarãesMolecular Oncology Research Center, Barretos Cancer Hospital, São Paulo 14784-400, Brazil.
Priscila Grecca PedrãoMolecular Oncology Research Center, Barretos Cancer Hospital, São Paulo 14784-400, Brazil.ORCID 0000-0002-0245-1089
Ricardo Dos ReisDepartment of Gynecologic Oncology, Barretos Cancer Hospital, São Paulo 14784-400, Brazil.ORCID 0000-0002-8271-3690
Adhemar Longatto-FilhoMolecular Oncology Research Center, Barretos Cancer Hospital, São Paulo 14784-400, Brazil.ORCID 0000-0002-5779-9752

Funding

São Paulo Research Foundation 2018/22017-6São Paulo Research Foundation 2020/00445-6
6 · The paper itself

Abstract

Cervical cancer is caused by HPV. Although it is the fourth most common type of cancer diagnosed and the fourth cause of cancer death, cervical cancer is nearly completely preventable because of the vaccination and screening available. The present review aims to map the initiatives conducted to implement or evaluate the implementation of HPV testing in Latin American countries. We performed the review by searching on PubMed in the English language and on grey literature, as most of the information about the guidelines used was found in governmental websites in the Spanish language. We only found information in eight countries concerning HPV testing as primary screening. Only Mexico has established HPV-based screening in all territories. There are three countries with regional implementation. Two countries with pilot studies indicated results that supported implementation. Finally, there are another two countries with a national recommendation. We have learned that HPV implementation is feasible and a very promising tool for reducing cervical cancer morbidity and mortality. The costs associated with saving lives and reducing suffering due to morbidity of a preventable disease must be pragmatically evaluated by the Latin America governments, and improving outcomes must be a mandatory priority for those that are responsible for addressing an organized system of cervical cancer screening.

Indexed as

cervical cancerHPV-based screeningHPV testLatin America

Identifiers

PMID35681590
PMCPMC9179482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.